With over 93318.0 Artelo Biosciences Inc. (ARTL) shares trading Wednesday and a closing price of $1.11 on the day, the dollar volume was approximately $0.1 million. The shares have shown a negative weekly performance of -9.60% and its price on 07/28/20 lost nearly -1.77%. Currently, there are 3.47M common shares owned by the public and among those 3.35M shares have been available to trade.
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 1 analysts who have offered their price forecasts for ARTL have a consensus price objective of $8.00. The analysts have set the share’s price value over the next 12 months at a high of $8.00 and a low of $8.00 should the stock experience a downside. Incidentally, analysts’ outlook for the Artelo Biosciences Inc. stock is 3.00 for the next 12 months. But an upside of 86.13% will see the stock hit the forecast high price target while mean target price for the stock is $8.00.
Insiders at the company have transacted a total of 10 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 9 of these insider trades were purchases, accounting for 65,334 shares. Insider sales of the common stock occurred on 1 occasions, with total insider shares sold totaling 17,500 shares.
Shares of Artelo Biosciences Inc. (NASDAQ: ARTL) opened at $1.16, up $0.03 from a prior closing price of $1.13. However, the script later closed the day at $1.11, down -1.77%. The company’s stock has a 5-day price change of -9.60% and -1.97% over the past three months. ARTL shares are trading -58.15% year to date (YTD), with the 12-month market performance down to -66.86% lower. It has a 12-month low price of $0.61 and touched a high of $4.42 over the same period. Currently, 93318.0 shares have been traded, compared to an average intraday trading volume of 258.68K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -8.05%, -13.16%, and -33.34% respectively.
Institutional ownership of Artelo Biosciences Inc. (NASDAQ: ARTL) shares accounts for 0.30% of the company’s 3.47M shares outstanding. Mutual fund holders own –, while other institutional holders and individual stakeholders account for 20.83% and — respectively.
It has a market capitalization of $5.31M. The earnings-per-share (ttm) stands at -$1.35. Price movements for the stock have been influenced by the stock’s volatility, which stands at 6.14% over the week and 10.77% over the month.
Analysts forecast that Artelo Biosciences Inc. (ARTL) will achieve an EPS of -$0.36 for the current quarter, -$0.38 for the next quarter and -$1.64 for 2021. The lowest estimate earnings-per-share for the quarter is -$0.36 while analysts give the company a high EPS estimate of -$0.36. Comparatively, EPS for the current quarter was -$0.17 a year ago. Earnings per share for the fiscal year are expected to decrease by -336.10%, and 0.60% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 1 brokerage firm advisors rate Artelo Biosciences Inc. (ARTL) as a “Hold” at a consensus score of 3.00. Specifically, 0 Wall Street analysts polled rate the stock as a buy, while 1 of the 1 advise that investors “hold,” and 0 rated it as a “Sell.”